Follow us on Twitter
twitter icon@FreshPatents


G Proteins patents

      

This page is updated frequently with new G Proteins-related patent applications.




 Method for attaching one or more polynucleotide binding proteins to a target polynucleotide patent thumbnailnew patent Method for attaching one or more polynucleotide binding proteins to a target polynucleotide
The invention relates to new methods of attaching one or more polynucleotide binding proteins to a target polynucleotide. The invention also relates to new methods of characterising target polynucleotides..
Oxford Nanopore Technologies Ltd.


 Bardcoded protein array for multiplex single-molecule interaction profiling patent thumbnailnew patent Bardcoded protein array for multiplex single-molecule interaction profiling
Methods for attaching barcodes to polypeptides are provided. Methods for detecting molecular interactions at the single molecule level are provided.
President And Fellows Of Harvard College


 A  directing proteins to specific loci in the genome and uses thereof patent thumbnailnew patent A directing proteins to specific loci in the genome and uses thereof
Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a dna localization component and an effector molecule, wherein the dna localization component and the effector molecule are capable of being operatively linked via a non-covalent linkage..
Poseida Therapeutics, Inc.


 Rhamnose promoter expression system patent thumbnailnew patent Rhamnose promoter expression system
The prokaryotic signal sequence is selected from signal peptides of periplasmatic binding proteins for sugars, amino acids, vitamins and ions. The expression of the nucleic acid sequence is controlled by the promoter region.

 Human lambda light chain mice patent thumbnailnew patent Human lambda light chain mice
Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


 Dual receptor antagonistic antigen-binding proteins and uses thereof patent thumbnailnew patent Dual receptor antagonistic antigen-binding proteins and uses thereof
This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. Antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases.
Amgen Inc.


 Specific sorbent for binding proteins and peptides, and separation method using the same patent thumbnailnew patent Specific sorbent for binding proteins and peptides, and separation method using the same
Sorbent comprising a solid support material, the surface of which comprises first residues comprising a binuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms n, o, s, and second residues comprising a mononuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms n, o, s.. .
Instraction Gmbh


 Activity of fe-s cluster requiring proteins patent thumbnailActivity of fe-s cluster requiring proteins
The present invention is related to a recombinant host cell, in particular a yeast cell, comprising a dihydroxy-acid dehydratase polypeptide. The invention is also related to a recombinant host cell having increased specific activity of the dihydroxy-acid dehydratase polypeptide as a result of increased expression of the polypeptide, modulation of the fe—s cluster biosynthesis of the cell, or a combination thereof.
Butamax Advanced Biofuels Llc


 Antigen-binding proteins that activate the leptin receptor patent thumbnailAntigen-binding proteins that activate the leptin receptor
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (lepr), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind lepr and activate lepr signaling.
Regeneron Pharmaceuticals, Inc.


 Hybrid suppressor trna for vertebrate cells patent thumbnailHybrid suppressor trna for vertebrate cells
This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal trna's, orthogonal aminoacyl-trna synthetases, orthogonal pairs of trna's/synthetases and unnatural amino acids.
Ambrx, Inc.


Dual specific binding proteins having a receptor sequence

Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie, Inc.

Peptide tags for labeling proteins by fusion, and antibodies for the detection thereof

Peptide tags (tags) are provided for their fusion to proteins at the n-terminal or c-terminal ends, which are defined by a series of structural and functional properties that define their safety with regard to the modification of the structure or biological function of the protein or peptide to which they are fused, and wherein the tag-protein is selected from a group consisting of a fragment of phl p 2 pheleum pratense , a fragment of hev b 6.02 hevea brasiliensis, and a fragment of amb t 5 ambrosia trifida, or a combination thereof. Methods are also provided for the production and detection of these recombinant fusion proteins as well as specific antibodies that bind to these tags..
Instituto De BiologÍa Molecular De Barcelona- Consejo Superior De Investigaciones Cientificas

Methods for making conjugates from disulfide-containing proteins

The invention provides methods to prepare protein conjugates from proteins having at least four accessible cysteine residues. In one embodiment, an antibody with four reducible disulfide linkages is reduced to provide four pairs of free cysteines.
Novartis Ag

N-acetylglucosamine sugar chain group-containing compound, carrier compound for drug delivery, drug preparation, and drug delivery system

An n-acetylglucosamine sugar chain group-containing compound which can easily reach cells/sites on which a vimentin and/or desmin protein(s) is/are exposed, which compound has excellent affinity to n-acetylglucosamine sugar chain-recognizing proteins; a drug delivery carrier compound comprising the compound: a preparation using the drug delivery earner compound; and a drug delivery system; are provided. These are an n-acetylglucosamine sugar chain group-containing compound having a weight average molecular weight within the range of 15,000 to 100,000; a drug delivery carrier compound comprising the compound; a preparation using the drug delivery carrier compound; and a drug delivery system..
Somar Corporation

Methods and compositions for wound treatment

The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.. .
Leidos, Inc.

T cell receptor-like antibodies specific for a wti peptide presented by hla-a2

The present invention provides antigen binding proteins that specifically bind to wilms' tumor protein (wt1), including humanized, chimeric and fully human antibodies against wt1, antibody fragments, chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to hla-a0201-restricted wt1 peptide.
Eureka Therapeutics, Inc.

Hybridoma cell lines (my-c-cc0c2-235-3h8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)

Monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human my-c are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (elisa) for the specific, cross-reactivity-free quantitative determination of my-c in serum, plasma, whole blood or other body fluid.
Martin-luther-universitÄt Halle-wittenberg

Asgr inhibitors

Antigen binding proteins that interact with asgr, asgr-1 and/or asgr-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of asgr, asgr-1 and/or asgr-2 antigen binding proteins.
Amgen Inc.

Pd-1 binding proteins and methods of use thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to programmed death-1 (pd-1) and modulate the expression and/or activity of pd-1.. .
Celgene Corporation

Single-chain multivalent binding protein compositions and methods

Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scdvd and scdvdfab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).. .
Abbvie Inc.

Method for treating prostatitis utilizing pore-forming protein proaerolysin

The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins..
Sophiris Bio, Corp.

Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof

The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders..
Constellation Pharmaceuticals, Inc.

Individualized cancer therapy

In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and rna from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2d dige and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate rna interference expression cassette to, directly or indirectly, modulate the expression of genes encoding such prioritized proteins; (i) incorporating said cassette into an appropriate delivery vehicle; and (j) providing the patient with an effective amount of the delivery vehicle to directly or indirectly, modify the expression (i.e., production) of such proteins.. .
Gradalis, Inc.

Methods and compositions for genomic target enrichment and selective dna sequencing

It has been established that one or more large double stranded dna fragments (each 2,000 to 40,000 base pairs in size) can be captured and isolated from genomic dna fragments using sequence specific pna hybridization probes. Compositions and methods for enrichment of a multiplicity of long dna sequences selected from the genome of any eukaryote are provided.
Petaomics, Inc.

Anti-activin a antibodies and uses thereof

The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.

Mrka polypeptides, antibodies, and uses thereof

The present disclosure provides mrka binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to mrka and induce opsonophagocytic killing of klebsiella (e.g., klebsiella pneumoniae). The present disclosure also provides methods of reducing klebsiella (e.g., klebsiella pneumoniae) or treating or preventing klebsiella (e.g., klebsiella pneumoniae) infection in a subject comprising administering mrka binding proteins, e.g., antibodies or antigen-binding fragments thereof, mrka polypeptides, immunogenic fragments thereof, or polynucleotides encoding mrka or immunogenic fragments thereof to the subject..
Medimmune, Llc

Methods of treatment using hemopexin compositions

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof..
Csl Behring Ag

Method for high-throughput protein detection with two antibody microarrays

The invention provides a method for detecting one or more biological ligands, where the method generally uses two arrays of biological reagents. The two arrays have two different functionalities: the first array captures the ligands on the array; and the second array delivers detecting reagents to the captured ligands.

Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Embodiments of the invention provide swallowable devices, preparations and methods for delivering therapeutic agents within the gi tract such as neutralizing proteins (np) particularly antibodies which neutralize interleukins. Many embodiments provide a swallowable device e.g., a capsule for delivering various agents into the intestinal wall (iw).
Rani Therapeutics, Llc

Continuous process for separation of proteins

Disclosed is a continuous process for separating or extracting proteins from a low grade mixture of a protein of interest, other proteins, impurities, and salts in a continuous simulated moving bed separation process. The invention provides for direct extraction of heme protein and plant protein from a crude mixture of such proteins, other proteins, impurities and salts using the chromatographic technique of simulated moving bed (smb) continuous chromatography.
Orochem Technologies, Inc.

Compounds and methods for the targeted degradation of bromodomain-containing proteins

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a vhl ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein.
Yale University

Protein detection method using mass spectrometry

The present invention provides: a method of pretreating a serum or plasma sample for detection of a protein or a plurality of proteins of interest in a serum or plasma sample via mass spectrometry and a method of detecting such a protein or proteins, wherein proteins such as albumin present in abundance in a sample are removed in a convenient manner, thereby making it possible to collect digested peptides from the protein of interest. Specifically, the present invention provides a method of pretreating a sample for detecting proteins in a serum or plasma sample via mass spectrometry, comprising a step of adding a protease to the sample under non-denaturing conditions to digest proteins and a step of separating the obtained peptides from undigested proteins, and a method of detecting proteins, comprising subjecting the obtained peptides to mass spectrometry..
Shimadzu Corporation

Method of improving the movement of a target polynucleotide with respect to a transmembrane pore

The invention relates to improving the movement of a target polynucleotide with respect to a transmembrane pore when the movement is controlled by a polynucleotide binding protein. The invention also relates to improved transmembrane pores and polynucleotide binding proteins..
Oxford Nanopore Technologies Ltd.

Novel glycosyltransferase gene and use thereof

Provided is a polynucleotide for encoding a protein that exhibits activity for transferring a sugar to a hydroxyl group at position 7 of a flavone, particularly flavone 4′-glucoside. A polynucleotide selected from the group consisting of: (a) polynucleotides comprising a base sequence of seq id no.: 1 or seq id no.: 5; (b) polynucleotides that hybridize, under stringent conditions, with polynucleotides comprising a base sequence complementary to a base sequence of seq id no.: 1 or seq id no.: 5, wherein the polynucleotides encode a protein that exhibits activity for transferring a sugar to a hydroxyl group at position 7 of a flavone; (c) polynucleotides for encoding proteins comprising an amino acid sequence of seq id no.: 2 or seq id no.: 6; (d) polynucleotides for encoding proteins comprising an amino acid sequence in which one or more amino acids have been deleted, substituted, inserted, and/or added in an amino acid sequence of seq id no.: 2 or seq id no.: 6, the polynucleotides exhibiting activity for transferring a sugar to a hydroxyl group at position 7 of a flavone; and the like..
Suntory Holdings Limited

Il-1 binding proteins

Proteins that bind il-1α and il-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing il-1-related disorders and for detecting il-1α and il-1β in cells, tissues, samples, and compositions.. .
Abbvie Inc.

Novel glycosaminoglycan-antagonising fusion proteins and methods of using same

The present invention relates to novel monomeric fusion proteins derived from human gag binding proteins such as chemokines with increased glycosaminoglycan (gag) binding affinity and knocked-out or reduced gpcr activity compared to wild type gag binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.. .
Antagonis Biotherapeutics Gmbh

Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase

The present invention relates to a method for the production of a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 as well as a method for selecting from a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide.. .
Eidgenoessische Technische Hochschule Zurich

Expression systems

The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a t cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic b cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture..
Glaxosmithkline Biologicals S.a.

Engineered cellular pathways for programmed autoregulation of differentiation

The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type.
The Trustees Of Princeton University

Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks

Methods and compositions for gene disruption, gene editing or gene stacking within a fad2 loci by cleaving, in a site directed manner, a location in a fad2 gene in a soybean cell, to generate a break in the fad2 gene and then optionally integrating into the break a nucleic acid molecule of interest is disclosed.. .
Sangamo Biosciences, Inc.

Recombinant host cell for expressing proteins of interest

The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (poi) from a host cell.
Lonza Ltd.

Recombinant rna particles and methods of producing proteins

The present invention provides compositions and methods for the production and delivery of recombinant double-stranded rna molecules (dsrna) encoding heterologous proteins, which can be useful for various therapeutic purposes as well as for the production of desired proteins. The compositions contain engineered double-stranded rna particles (dsrps) that can contain a double-stranded rna molecule that can be a genome or portion of a genome, which can be enclosed in a capsid or coat protein.
Synthetic Genomics, Inc.

Hybridoma cell lines (my-c-cc0c2-259-1 a4) and use thereof for producing a monoclonal antibody against human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)

Monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human my-c are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (elisa) for the specific, cross-reactivity-free quantitative determination of my-c in serum, plasma, whole blood or other body fluid.
Martin- Luther-universitaet Halle-wittenberg

Methods of treatment using alpha-1-antitrypsin compositions

A streamlined method for purifying alpha-1-antitrypsin (aat) from an aat-containing protein mixture, such as coh fraction iv precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect aat.
Csl Behring L.l.c.

Vhnar anti-cytokine domains

The present invention concerns therapeutic compositions containing proteins that are the variable regions of ignar immunoglobulins, denominated vnar, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.. .
Laboratorios Silanes S.a. De C.v.

Peptidomimetic compounds

The present invention relates to inhibitors of protein-protein interactions (ppi). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer.
Noliva Therapeutics Llc

Compositions and methods for treating itching, gingivostomatitis, and demodectic mange

Provided are methods for treating itching caused by allergy, include itching associated with parasite-mediated inflammation (e.g., demodicosis, stomatitis, dermatophytosis, etc.), comprising administration to a mammalian subject in need thereof a therapeutically effective amount of a heat-treated, fractionated thymus extract composition (e.g., thyex-1-6a and -6b compositions, comprising proteins or polypeptides having molecular weights in the range of 3.5 kda to 30 kda), in combination with or formulated with colostrum, to provide for reducing itching in the subject. Combination or adjunctive therapies comprising administration of a heat-treated, fractionated thymus extract composition in combination with or formulated with colostrum, and including at least one additional anti-parasitic, anti-bacterial, anti-fungal, anti-viral agent, or homeopathic agent are also provided.
Cmi Research Management, Llc

Fn14 binding proteins and uses thereof

The present disclosure provides proteins comprising antibody antigen binding domains that bind to fn14 and uses thereof. The present disclosure also provides methods for treating wasting disorders, such as cachexia..
La Trobe University

Gitr antigen binding proteins

Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Amgen Inc.

Prolactin receptor binding proteins and uses thereof

The present invention encompasses prlr binding proteins. Specifically, the invention relates to antibodies that are chimeric, cdr grafted and humanized antibodies.
Abbvie Inc.



G Proteins topics:
  • G Proteins
  • Antibodies
  • Immunoglobulin
  • Metalloprotein
  • Chemotherapeutic Agent
  • Kinase Inhibitor
  • Tetrapeptide
  • Apoptosis Protein
  • Topoisomerase
  • Peptidomimetic
  • Fractionation
  • Medical Treatment
  • Chromatograph
  • Encapsulation
  • Electrospraying


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4791

    file did exist - 2409

    1 - 1 - 52